Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Domatinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.46 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.46 |
| ▸ | INSR known ✓ | P06213 | 1/20 | 0.46 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 17/20 | 0.88 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.88 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.88 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.88 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.88 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.88 |
| ▸ | KDM1A | O60341 | 1/20 | 0.88 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Domatinostat SCHEMBL1613945 | 1.00 | HDAC1 (0.88) | HDAC1HDAC2HDAC3HDAC10HDAC11 | |
| Domatinostat SCHEMBL1613947 | 1.00 | HDAC1 (0.88) | HDAC1HDAC2HDAC3HDAC10HDAC11 | |
| Domatinostat SCHEMBL1614675 | 0.95 | HDAC1 (0.90) | HDAC1HDAC2HDAC3HDAC10HDAC11 | |
| Domatinostat SCHEMBL1614674 | 0.95 | HDAC1 (0.90) | HDAC1HDAC2HDAC3HDAC10HDAC11 | |
| Domatinostat SCHEMBL31096922 | 0.94 | HDAC1 (0.97) | HDAC1HDAC2HDAC3HDAC10HDAC11 | |
| Domatinostat SCHEMBL1613939 | 0.94 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC10HDAC11 | |
| Domatinostat SCHEMBL30477018 | 0.94 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC10HDAC11 | |
| Domatinostat SCHEMBL1613943 | 0.94 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC10HDAC11 | |
| Domatinostat SCHEMBL1614634 | 0.93 | HDAC1 (0.98) | HDAC1HDAC2HDAC3HDAC10HDAC11 | |
| Domatinostat SCHEMBL1613921 | 0.93 | HDAC1 (0.98) | HDAC1HDAC2HDAC3HDAC10HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | ABL1 3525/4885EGFR 2006/4885ERBB2 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.